Eternity Healthcare to Develop a Noninvasive Saliva-Based Sugar Monitor Device to Test for Diabetes

PHOENIX and VANCOUVER, British Columbia, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Eternity Healthcare Inc. (OTCBB:ETAH), a leading medical device and diagnostic company with special focus on diabetes management, announced today that they are in development of a noninvasive sugar monitoring device using saliva instead of blood.

There are an estimated 28 million diabetics in the United States and this number is growing. The worldwide number of diabetics is estimated to be over 200 million. Diabetic patients are divided into type 1 and type 2. Type 1 diabetics require painful finger pricking and insulin injections 3-5 times a day and about 50% of the type 2 diabetics also require painful finger pricking and insulin injections.

Dr. Salari, C.E.O. states that "Eternity Healthcare will be the first company to focus on the development of an alternative saliva based glucose monitoring test. This new test should reduce the patient's reliance on painful finger pricking and blood collection."

Currently the diabetic patients require using blood drawn from fingertips for testing of the blood sugar level. A drop of blood from the fingertip is placed on a strip which is then inserted into a monitoring device, known as glucose monitor device. Using electrochemical reaction, the device provides the sugar level on which the patients determine whether he requires an insulin injection or not and if so, what dosage. Over 10 million glucose monitor devices, and several hundred million test strips are sold annually. The Global Blood Glucose Monitoring Devices Market was Valued at $8.9 billion in 2010. The Worldwide Glucose monitoring devices market is expected to be more than US $16 Billion by 2014.

The major marketers of glucose monitoring devices are big pharmaceutical companies such as Bayer, Abbott, Roche, and several others. Pricking finger to draw blood is not a comfortable task. Some patients need to prick their fingers 3-5 times a day which is not a pleasant adventure. A sugar test that implies different factors in the saliva to determine blood glucose concentration in the body is highly desirable.

Eternity Healthcare, which focuses on various aspects of diabetes management, including a needle-free injection device, will be the first company to focus on the development of an alternative glucose monitor test. The new test should reduce the patient's dependence to painful finger pricking and blood collection.

About Eternity Healthcare Inc.

Eternity Healthcare Inc. (OTCBB:ETAH) is a biopharmaceutical company with technologies in medical diagnostics and medical devices. We are currently focused on Comfort In ™ a needle free injection system. Our products are sold to healthcare professionals, for use in physicians' offices, pharmacies, and to consumers directly. Our products are all manufactured under strict compliance with GMP, ISO 9001 and ISO 13485 procedures, with special emphasis on quality control at each and every stage of production. More information on Eternity Healthcare Inc. can be found on the website.

Safe Harbor Statement

This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as ETAH or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

CONTACT: Company contact: Lena Kuang Executive Assistant (855) 324-1110 Investor Relations Contact: Bryan Andrew Wall Street Media Group Inc. (480) 588-8658 info@wallstreetmediagroup.comSource:Eternity Healthcare, Inc.